Hypothyroidism. Other hypothyroidism
Conditions
Interventions
In the present before-and-after semi-experimental study, 49 patients with hypothyroidism between the ages of 30 and 50 years with TSH levels greater than 10 µIU/mL and T4 less than 4 ng/dL and serum A
Sponsors
Dezfoul University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients with hypothyroidism The ages between 30 and 50 years old TSH levels greater than 10 µIU/mL T4 levels less than 4 ng/dL Serum Anti-TPO levels greater than 200 U/mL
Exclusion criteria
Exclusion criteria: History of thyroid surgery Thyroid malignancies Hypothyroidism resulting from hyperthyroidism treatment Other known autoimmune and rheumatic diseases Renal failure and malabsorption History of use of antithyroid drugs History of use of cytotoxics History of use of immunosuppressants History of use of immunomodulators History of use of glucocorticoids History of use of amiodarone, lithium, interferon, radioiodine, History of chemotherapy History of use of supplements containing vitamin B1 pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroxine hormone (T4). Timepoint: Before the start of the study and 1 month and 2 months after starting to take vitamin B1 tablets. Method of measurement: Blood collection from the patient and serum separation.;Thyroid-stimulating hormone (TSH). Timepoint: Before the start of the study and 1 month and 2 months after starting to take vitamin B1 tablets. Method of measurement: Blood collection from the patient and serum separation.;Serum Anti-TPO. Timepoint: Before the start of the study and 1 month and 2 months after starting to take vitamin B1 tablets. Method of measurement: Blood collection from the patient and serum separation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum total cholesterol (TC). Timepoint: Before the start of the study and 1 and 2 months after receiving vitamin B1 tablets. Method of measurement: Blood collection and serum separation from the patient.;Serum LDL-C. Timepoint: Before the start of the study and 1 and 2 months after receiving vitamin B1 tablets. Method of measurement: Blood collection and serum separation from the patient.;Serum HDL-C. Timepoint: Before the start of the study and 1 and 2 months after receiving vitamin B1 tablets. Method of measurement: Blood collection and serum separation from the patient.;LDL-C to HDL-C ratio. Timepoint: Before the start of the study and 1 and 2 months after receiving vitamin B1 tablets. Method of measurement: Blood collection and serum separation from the patient.;Serum triglycerides (TG). Timepoint: Before the start of the study and 1 and 2 months after receiving vitamin B1 tablets. Method of measurement: Blood collection and serum separation from the patient.;Serum VLDL. Timepoint: Before the start of the study and 1 and 2 months after receiving vitamin B1 tablets. Method of measurement: Blood collection and serum separation from the patient.;Atherogenic index. Timepoint: Before the start of the study and 1 and 2 months after receiving vitamin B1 tablets. Method of measurement: Blood collection and serum separation from the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Akbar Oroojan
Dezfoul University of Medical Sciences
Outcome results
None listed